The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Open accessAbstract
BACKGROUND: The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease. OBJECTIVES: The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease. SEARCH METHODS: We searched MEDLINE, EMBASE and the Cochrane Library from inception to 30 October 2015. Review articles and conference proceedings were also searched to identify additional studies. SELECTION CRITERIA: Randomized controlled trials (RCTs) of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion. DATA COLLECTION AND ANALYSIS: Data were extracted by two independent observers based on the intention-to-treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria. MAIN RESULTS: Thirteen RCTs (n = 1211 patients) of azathioprine and 6-mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was no statistically significant difference in clinical remission rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55). There was no statistically significant difference in clinical improvement rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62). There was a statistically significant difference in steroid sparing (defined as prednisone dose < 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty-four per cent (47/163) of azathioprine patients were able to reduce their prednisone dose to < 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. There was no statistically significant difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid-free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90). The combination of azathioprine and infliximab was significantly superior to infliximab alone for induction of steroid-free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid-free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47). Azathioprine or 6-mercaptopurine therapy was found to be no better at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49) and 5-aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91). There were no statistically significant differences in withdrawals due to adverse events between azathioprine or 6-mercaptopurine and methotrexate (RR 0.78, 95% CI 0.23 to 2.71); between azathioprine or 6-mercaptopurine and 5-aminosalicylate or sulfasalazine (RR 0.98, 95% CI 0.38 to 2.54); between azathioprine and infliximab (RR 1.47, 95% CI 0.96 to 2.23); or between the combination of azathioprine and infliximab and infliximab (RR 1.16, 95% CI 0.75 to 1.80). Common ad
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(2008) · Cited by 3,790
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
A method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
Pearson, D. C., May, G. R., Fick, G. H., & Sutherland, L. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00009 · Cited by 950
Self-citationChapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
Markowitz, J., Grancher, K., Kohn, N., Lesser, M., & Daum, F. (2000) · Gastroenterology · doi:10.1053/gast.2000.18144 · Cited by 716
Clinical, biological, and endoscopic picture of attacks of Crohn's disease
Modigliani, R., Mary, J.-Y., Simon, J.-F., Cortot, A., Soule, J.-C., Gendre, J.-P., & Rene, E. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90002-i · Cited by 699
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
The clinical pharmacology of 6-mercaptopurine
Lennard, L. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220605 · Cited by 647
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
A controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
Connell, W. R., Kamm, M. A., Ritchie, J. K., & Lennard-Jones, J. E. (1993) · Gut · doi:10.1136/gut.34.8.1081 · Cited by 510
Keele, G. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91022-2 · Cited by 499
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
Bouhnik, Y., Scemama, G., Taï, R., Matuchansky, C., Rambaud, J.-C., Lémann, M., Modigliani, R., & Mary, J.-Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90402-x · Cited by 466
Clinical features and natural history of Crohn's disease
Mekhjian, H. S., Switz, D. M., Melnyk, C. S., Rankin, G. B., & Brooks, R. K. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90389-5 · Cited by 406
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
LÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE
O'Donoghue, D. P., Dawson, A. M., Powell-Tuck, J., Bown, R. L., & Lennard-Jones, J. E. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92524-2 · Cited by 332
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Willoughby, J. M. T., Beckett, J., Kumar, P., & Dawson, A. M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90268-6 · Cited by 314
Safety of azathioprine in pregnancy in inflammatory bowel disease
Alstead, E. M., Ritchie, J. K., Lennard-Jones, J. E., Farthing, M. J. G., & Clark, M. L. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91027-4 · Cited by 276
Sandborn, W. J. (1996) · PubMed · Cited by 274
National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
Singleton, J. W., Law, D. H., Kelley, M. L., Mekhjian, H. S., & Sturdevant, R. A. L. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90386-x · Cited by 263
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 253
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Panés, J., López–SanRomán, A., Bermejo, F., García–Sánchez, V., Esteve, M., Torres, Y., Domènech, E., Piqueras, M., Gomez–García, M., Gutiérrez, A., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.009 · Cited by 252
Khan, K. J., Dubinsky, M. C., Ford, A. C., Ullman, T. A., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.64 · Cited by 246
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
D'Haens, G., Geboes, K., Ponette, E., Penninckx, F., & Rutgeerts, P. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70027-1 · Cited by 246
Sandborn, W. J., Tremaine, W. J., Wolf, D. C., Targan, S. R., Sninsky, C. A., Sutherland, L. R., Hanauer, S. B., McDonald, J. W. D., Feagan, B. G., Fedorak, R. N., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70445-2 · Cited by 237
Self-citationMaté-Jiménez, J., Hermida, C., Cantero-Perona, J., & Moreno-Otero, R. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012110-00010 · Cited by 227
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease
Dejaco, C., Harrer, M., Waldhoer, T., Miehsler, W., Vogelsang, H., & Reinisch, W. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01793.x · Cited by 224
Surfactants in Severe Hyaline-Membrane Disease - Reply
Do, S. (1978) · The Lancet · Cited by 218
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
Ewe, K., Press, A. G., Singe, C. C., Stufler, M., Ueberschaer, B., Hommel, G., & Büschenfelde, K.-H. M. Z. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90709-l · Cited by 217
A controlled trial of azathioprine in Crohn's disease
Rosenberg, J. L., Levin, B., Wall, A. J., & Kirsner, J. B. (1975) · The American Journal of Digestive Diseases · doi:10.1007/bf01070829 · Cited by 201
Oren, R., Moshkowitz, M., Odes, S., Becker, S., Keter, D., Pomeranz, I. S., Shirin, H., Shirin, C., Reisfeld, I., Broide, E., et al. (1997) · PubMed · Cited by 200
Neurath, M. F., Wanitschke, R., Peters, M., Krummenauer, F., zum Büschenfelde, K.-H. M., & Schlaak, J. F. (1999) · Gut · doi:10.1136/gut.44.5.625 · Cited by 199
PARKINSON, T. (1947) · PubMed · Cited by 199
Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01297.x · Cited by 198
Colombel, J. ‐., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rutgeerts, P., Tang, K. L., Oortwijn, A., Bevelander, G. S., Cornillie, F. J., & Sandborn, W. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13139 · Cited by 197
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Rhodes, J., Beck, P., Bainton, D., & Campbell, H. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90598-8 · Cited by 184
Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease
O'Brien, J. J., Bayless, T. M., & Bayless, J. A. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90457-v · Cited by 172
Treatment of Crohn's Disease with Azathioprine: A Controlled Evaluation
Klein, M., Binder, H. J., Mitchell, M., Aaronson, R., & Spiro, H. (1974) · Gastroenterology · doi:10.1016/s0016-5085(74)80166-6 · Cited by 158
Mantzaris, G. J., Christidou, A., Sfakianakis, M. E., Roussos, A., Koilakou, S., Petraki, K., & Polyzou, P. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20777 · Cited by 158
Ardizzone, S., Bollani, S., Manzionna, G., Imbesi, V., Colombo, E. M., & Porro, G. B. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00372-4 · Cited by 150
National Cooperative Crohn's Disease Study: Study design and conduct of the study
Winship, D. H., Summers, R. W., Singleton, J. W., Best, W. R., Becktel, J. M., Lenk, L. F., & Kern, F. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90383-4 · Cited by 144
Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease.
Korelitz, B. I., Adler, D. J., Mendelsohn, R. A., et al. (1993) · PubMed · Cited by 143
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Chande, N., Tsoulis, D. J., & MacDonald, J. K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub4 · Cited by 121
Self-citationArnold, R., Hulst, M. V., Neuhof, C., Schwarting, H., Becker, H. D., & Creutzfeldt, W. (1982) · Gut · doi:10.1136/gut.23.4.285 · Cited by 112
Reinshagen, M., Schütz, E., Armstrong, V. W., Behrens, C., von Tirpitz, C., Stallmach, A., Herfarth, H. H., Stein, J. M., Bias, P., Adler, G., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.086215 · Cited by 109
Os, E. C. V., Zins, B., Sandborn, W. J., Mays, D. C., Tremaine, W. J., Mahoney, D. W., Zinsmeister, A. R., & Lipsky, J. J. (1996) · Gut · doi:10.1136/gut.39.1.63 · Cited by 106
Reinisch, W., Panés, J., Lémann, M., Schreiber, S., Feagan, B. G., Schmidt, S. L., Sturniolo, G. C., Mikhailova, T. L., Alexeeva, O., Sanna, L., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02024.x · Cited by 102
Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease
Dassopoulos, T., Dubinsky, M. C., Bentsen, J. L., Martin, C. F., Galanko, J. A., Seidman, E. G., Sandler, R. S., & Hanauer, S. B. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12555 · Cited by 80
Miehsler, W., Reinisch, W., Moser, G., Gangl, A., & Vogelsang, H. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03622.x · Cited by 66
Murdoch, J., & Barnes, J. A. (1986) · doi:10.1007/978-1-349-09107-2_6 · Cited by 27
Israeli, E., Goldin, E., Fishman, S., Konikoff, F. M., Lavy, A., Chowers, Y., Melzer, E., Lahat, A., Mahamid, M., Shirin, H., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12640 · Cited by 22
A double-blind trial of azathioprine in Crohn's disease.
Jm, W., Kumar, P., Beckett, J., & Dawson, A. M. (1971) · PubMed · Cited by 20
Khanna, R., Levesque, B. G., Bressler, B. L., Zou, G., Stitt, L., Greenberg, G. R., Panaccione, R., Bitton, A., Paré, P., Vermeire, S., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/s1873-9946(14)60005-2 · Cited by 19
Endoscopic healing of Crohn's Ileo-colitis with azathioprine
Colombel, J. F., Lémann, M., Bouhnik, Y., Duclos, B., Soulé, J. C., Lerebours, É., Mary, J., & GETAID, T. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)80985-x · Cited by 14
Cited by
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Metadata
- Authors
- Prefontaine, E., MacDonald, J. K., & Sutherland, L. R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-06-16
- Volume
- 10
- Issue
- 6
- Pages
- CD000545-CD000545
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2072179061
- Cited by
- 604
- References
- 64
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.